Biotechnology USA-based tumor drug resistance specialist Deciphera Pharmaceuticals saw its shares close down 2.7% at $15.94 yesterday, after it announced findings of a planned exploratory analysis of data from the INTRIGUE Phase III clinical study of Qinlock (ripretinib) using circulating tumor DNA (ctDNA) from a subgroup of patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib who harbor mutations in KIT exon 11 and 17/18 only. 4 January 2023